BiotechTube

NDV-3 vaccine with alum IM + NDV-3 vaccine without alum IM + Placebo with alum IM + NDV-3 vaccine without alum ID

Phase 1Completed
0 watching 0 views this week💤 Quiet
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Staphylococcal Infections

Conditions

Staphylococcal Infections, Yeast Infections, Candidiasis

Trial Timeline

Sep 1, 2011 → Dec 1, 2012

NCT ID
NCT01447407

About NDV-3 vaccine with alum IM + NDV-3 vaccine without alum IM + Placebo with alum IM + NDV-3 vaccine without alum ID

NDV-3 vaccine with alum IM + NDV-3 vaccine without alum IM + Placebo with alum IM + NDV-3 vaccine without alum ID is a phase 1 stage product being developed by United Therapeutics for Staphylococcal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01447407. Target conditions include Staphylococcal Infections, Yeast Infections, Candidiasis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01447407Phase 1Completed

Competing Products

20 competing products in Staphylococcal Infections

See all competitors
ProductCompanyStageHype Score
CeftobiproleJohnson & JohnsonPhase 1
33
CeftobiproleJohnson & JohnsonPhase 1
33
Daptomycin + VancomycinMerckApproved
85
Daptomycin 4 mg/kg + Comparator: vancomycin + Daptomycin 6 mg/kgMerckPhase 3
77
V710 + PlaceboMerckPhase 1
33
V710 + Comparator: PlaceboMerckPhase 1
33
V710 (30 µg) with MAA + V710 (30 µg) without MAAMerckPhase 1
33
Daptomycin + VancomycinMerckApproved
85
DaptomycinNovartisApproved
85
SA4Ag vaccinePfizerPhase 1
32
Staphylococcus aureus 4-Antigen (SA4Ag) VaccinePfizerPhase 2
51
linezolid (Zyvox)PfizerPre-clinical
22
Staphylococcus aureus 4-antigen vaccine + PlaceboPfizerPhase 2
51
TigecyclinePfizerApproved
84
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + PlaceboPfizerPhase 1
32
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + SA3Ag vaccine + PlaceboPfizerPhase 1
32
NDV-3 investigational vaccineUnited TherapeuticsPhase 1
30
TD-1792 + VancomycinTheravance BiopharmaPhase 2
47
CeftobiproleBasilea PharmaceuticaPhase 1
28
human lactoferrin peptide 1-11AM-PharmaPhase 1/2
33

Other Products from United Therapeutics

TreprostinilApproved
82
RemodulinApproved
82
Remodulin (treprostinil sodium)Approved
82
Intravenous TreprostinilApproved
82
Intravenous/Subcutaneous Treprostinil; Oral TreprostinilApproved
82